Rationale: Pruritus is a common symptom in patients with systemic sclerosis and has a tremendous effect on the quality of life. Nevertheless, current therapeutic options are limited. The pathogenesis of pruritus in systemic sclerosis is not completely understood; however, opiate-mediated neurotransmission has been postulated to be involved.
Patient concerns and diagnosis: We describe 4 female patients with systemic sclerosis suffering from severe pruritus, with an average 5D-itch score of 22.75.
Intervention and outcomes: Low-dose oral naloxone was initiated, followed by a significant improvement in the level of pruritus, reaching an average 5D-itch score of 7.5, after 6 and 12 months of treatment. None of the patients experienced side effects.
Lessons: Low-dose naloxone plays an important role in the management of pruritus in systemic sclerosis.
Copyright © 2022 the Author(s). Published by Wolters Kluwer Health, Inc.